CEFPODOXIME PROXETIL
Clinical safety rating: safe
Human studies have proved safety
Cefpodoxime proxetil is a prodrug that is de-esterified in vivo to cefpodoxime, a third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and disrupting peptidoglycan cross-linking, leading to cell lysis. It has broad-spectrum activity against Gram-positive and Gram-negative bacteria.
| Metabolism | Cefpodoxime proxetil is de-esterified to the active metabolite cefpodoxime by esterases in the intestinal wall and blood. Cefpodoxime is minimally metabolized. Approximately 29-33% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion. |
| Excretion | Renal excretion of unchanged drug (29-33%) and fecal/biliary elimination of inactive metabolites; 80% of radiolabeled dose recovered in urine and feces over 8 days. |
| Half-life | Terminal elimination half-life of cefpodoxime is 2.2-2.8 hours in healthy adults; prolonged to 5.9-9.8 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 13-14 hours in severe impairment (CrCl <10 mL/min). |
| Protein binding | 21-29% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.5-0.8 L/kg; distributes into blister fluid, bronchial mucosa, and pulmonary tissue, but penetration into CSF is poor. |
| Bioavailability | Oral bioavailability is 50% for the proxetil ester (increased to 60-70% when taken with food); absolute bioavailability of cefpodoxime from the prodrug is 50%. |
| Onset of Action | Oral: peak serum concentrations at 2-3 hours post-dose; clinical effect within 2-4 hours after administration. |
| Duration of Action | Duration of antibacterial activity is approximately 12 hours, supporting twice-daily dosing; extends in renal impairment. |
200 mg orally every 12 hours
| Dosage form | FOR SUSPENSION |
| Renal impairment | CrCl 30-49 mL/min: 200 mg every 12 hours; CrCl 10-29 mL/min: 200 mg every 24 hours; CrCl <10 mL/min: 200 mg every 24 hours |
| Liver impairment | No adjustment required for mild to moderate hepatic impairment; severe impairment (Child-Pugh Class C): use with caution, limited data available |
| Pediatric use | 2 months to 12 years: 5 mg/kg orally every 12 hours (max 200 mg/dose); >12 years: same as adult |
| Geriatric use | No specific dose adjustment required based on age alone; adjust dose based on renal function |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Antacids and H2 blockers decrease absorption May cause diarrhea including Clostridium difficile-associated diarrhea.
| Breastfeeding | Excreted in breast milk in low concentrations. M/P ratio not established. Consider benefits vs risks; use caution. |
| Teratogenic Risk | FDA Pregnancy Category B. Animal studies show no fetal harm; no adequate human studies. Risk cannot be ruled out. Use only if clearly needed. |
| Fetal Monitoring | Monitor for signs of hypersensitivity (rash, urticaria), gastrointestinal disturbances (diarrhea, pseudomembranous colitis), and superinfection. No specific fetal monitoring required. |
■ FDA Black Box Warning
None.
| Common Effects | Diarrhea |
| Serious Effects |
["Hypersensitivity to cefpodoxime proxetil, other cephalosporins, or any component of the formulation.","Known hypersensitivity to penicillins (potential cross-reactivity; caution advised)."]
| Precautions | ["Hypersensitivity reactions including anaphylaxis; cross-sensitivity among cephalosporins and penicillins possible.","Clostridioides difficile-associated diarrhea (CDAD).","Patients with renal impairment require dose adjustment.","Prolonged use may result in superinfection.","Safety in pregnancy (Category B) and lactation not established; use only if clearly needed."] |
| Food/Dietary | Take with food to enhance absorption. High-fat meals increase bioavailability. No specific dietary restrictions, but avoid alcohol to minimize side effects such as gastrointestinal upset or dizziness. |
Loading safety data…
| Fertility Effects | No adverse effects on fertility reported in animal studies. No human data available. |
| Clinical Pearls | Cefpodoxime proxetil is a third-generation cephalosporin with activity against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae. It is not effective against MRSA, Enterococcus, or Pseudomonas. The prodrug is de-esterified to active cefpodoxime. Absorbed best with food; administer with meals to enhance bioavailability. Dose adjustment required for CrCl <30 mL/min. Avoid in patients with penicillin allergy due to cross-sensitivity (~10%). Should not be used for viral infections or acute bronchitis in healthy adults due to lack of efficacy and risk of resistance. |
| Patient Advice | Take this medication exactly as prescribed, even if you feel better. Complete the full course to prevent antibiotic resistance. · Take with food to improve absorption and reduce stomach upset. · Common side effects include diarrhea, nausea, and headache. Contact your doctor if you experience severe diarrhea, rash, or difficulty breathing. · Store at room temperature away from moisture and heat. Shake the oral suspension well before each use. · Inform your doctor if you are pregnant, breastfeeding, or have a history of allergies, kidney disease, or intestinal problems like colitis. · Avoid alcohol while taking this medication to reduce the risk of adverse effects. |